Table 3.
Univariate/multivariate analysis of clinicopathological features and two-miRNA signature.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| P value | HR (95% CI) | β | P value | HR (95% CI) | ||
| Sex | ||||||
| Male | 0.608 | 0.676-1.258 | ||||
| Female | ||||||
| Age(years) | ||||||
| <60 | 0.000 | 1.367-2.581 | 0.353 | 0.110 | 0.983-2.337 | |
| ≥60 | ||||||
| Pathologic stage | ||||||
| Stage I-II | 0.000 | 2.715-5.146 | 0.276 | 0.560 | 0.555-3.379 | |
| Stage III-IV | ||||||
| T stage | ||||||
| T1+T2 | 0.000 | 2.251-4.145 | 0.191 | 0.650 | 0.569-2.976 | |
| T3+T4 | ||||||
| Nodal metastasis | ||||||
| N0 | 0.000 | 1.860-6.324 | 0.450 | 0.189 | 0.862-3.277 | |
| N1 | ||||||
| Distant metastatic | ||||||
| M0 | 0.000 | 3.081-5.762 | 0.960 | 0.000 | 1.355-3.633 | |
| M1 | ||||||
| Grade | ||||||
| G 1-2 | 0.000 | 1.877-3.748 | 0.363 | 0.125 | 0.896-2.453 | |
| G 3-4 | ||||||
| Two-miRNA signature PI | ||||||
| Low risk | 0.000 | 1.882-3.568 | 0.873 | 0.000 | 1.312-3.606 | |
| High risk | ||||||
Abbreviations: HR, hazard ratio; CI, confidence interval; PI, prognosis Index
* p value of <0.05 was considered statistically significant difference.